Glenmark USA to launch Leucovorin Calcium Injection in December 2025

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1951.10

prior close

₹1945.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.9%-0.8% vs market

Pharmaceuticals peers, median of 156sector+0.6%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.5

15m

+0.5

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.9-0.8+0.6-0.6

Next day

+0.9+2.0-1.2+1.1-0.3

+1.5+2.0-0.4+0.5+1.0

+0.6+1.2-0.6+0.1+0.4

-0.5+0.6-1.2-0.7+0.2

+0.4+0.9-0.5-0.6+1.0

+4.4+2.9+1.5+0.8+3.6

15d

+6.2+4.0+2.2+1.6+4.6

+3.2+1.1+2.1-1.9+5.1

+3.3+3.0+0.3-2.2+5.5

+16.3-4.0+20.3-6.5+22.8

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark's US arm will launch Leucovorin Calcium for Injection USP, 350 mg per vial Single-Dose Vial in December 2025. The product is bioequivalent and therapeutically equivalent to Hospira's reference listed drug. This expands Glenmark's institutional channel portfolio in the US. The target US market had annual sales of about 16.8 million dollars per IQVIA data through October 2025.

Likely market impact

Adds a new US institutional product. Market is modest at around 16.8 million dollars annually, so revenue impact is limited but supports US growth.